Trial Profile
A phase Ib/II study of ARQ 761 in patients selected for tumours with high levels of the biomarker NQ01
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 20 Jun 2018
Price :
$35
*
At a glance
- Drugs ARQ 761 (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Pancreatic cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 14 Jun 2018 According to an ArQule media relerase,this trial is conducted in partnership with the University of Texas Southwestern Medical Center.
- 04 May 2016 According to an ArQule media release, the first cohort of patients has been enrolled in this trial.
- 04 May 2016 According to an ArQule media release, status changed from planning to recruiting.